SAN DIEGO, Nov. 26, 2013 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive
Officer of Neurocrine Biosciences, will be presenting at two
investor conferences next week.
On December 3 at 2:15pm Eastern Time (11:15am Pacific Time) he will make a presentation
at the Deutsche Bank 2013 Biofest in Boston.
On December 4 at 11:30am Eastern Time (8:30am Pacific Time) he will make a presentation
at the 25th Annual Piper Jaffray Healthcare Conference
in New York City.
Both webcasts may be accessed live on the Company's website at
http://www.neurocrine.com. Listeners are encouraged to visit the
website approximately 5 minutes prior to the presentation to
download or install any necessary software. A replay of the
presentations will be available on the website approximately one
hour after the conclusion of each event and will be archived for
one month.
Neurocrine Biosciences, Inc. is a clinical stage drug discovery
company primarily focused on neurological and endocrine based
diseases and disorders. The Company discovers and develops
innovative pharmaceuticals, in diseases with high unmet medical
needs or where the existing drug classes are inadequate, through a
disciplined yet entrepreneurial process. Utilizing a portfolio
approach to drug discovery, Neurocrine has multiple small molecule
drug candidates at various stages of pharmaceutical development.
Neurocrine's two lead late stage clinical programs are elagolix, a
GnRH antagonist for women's health that is partnered with AbbVie
Inc., and a wholly owned VMAT2 inhibitor for the treatment of
movement disorders. Neurocrine intends to maintain certain
commercial rights to its VMAT2 inhibitor for evolution into a
fully-integrated pharmaceutical company. Neurocrine
Biosciences, Inc. news releases are available through the Company's
website via the internet at http://www.neurocrine.com.
SOURCE Neurocrine Biosciences, Inc.